Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer
NCT05377047 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 345
Last updated 2022-10-21
Summary
TAORMINA is an international, multicentre, randomised phase 3 trial for patients with oligometastatic breast cancer (OMBC) that will be allocated to combined stereotactic ablative radiotherapy (SABR) + systemic therapy (investigational arm) versus systemic therapy alone (control arm) as 1st line therapy.
Conditions
- Breast Cancer Stage IV
- Oligometastatic Disease
Interventions
- RADIATION
-
SABR
Stereotactic Ablative Radiotherapy is delivered to all metastatic lesions.
Sponsors & Collaborators
-
Sahlgrenska University Hospital
collaborator OTHER -
Azienda Ospedaliero-Universitaria Careggi
collaborator OTHER -
Region Örebro County
collaborator OTHER -
Skane University Hospital
collaborator OTHER -
Uppsala University Hospital
collaborator OTHER -
Karolinska University Hospital
collaborator OTHER -
University Hospital, Umeå
collaborator OTHER -
Sundsvall Hospital
collaborator OTHER -
Karlstad Central Hospital
collaborator OTHER -
Gävle Hospital
collaborator OTHER -
Centrallasarettet Västerås
collaborator OTHER -
Oslo University Hospital
collaborator OTHER -
St. Olavs Hospital
collaborator OTHER -
Haukeland University Hospital
collaborator OTHER -
University of Stavanger
collaborator OTHER -
University Hospital of North Norway
collaborator OTHER -
Vastra Gotaland Region
lead OTHER_GOV
Principal Investigators
-
Barbro K Linderholm, MD, PhD · Sahlgrenska University Hospital, Gothenburg
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-09-19
- Primary Completion
- 2025-12-31
- Completion
- 2027-12-31
Countries
- Sweden
Study Locations
More Related Trials
-
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
NCT03997123 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
NCT03808337 ·Status: RECRUITING ·Phase: PHASE2
-
Capecitabine + Bendamustine in Women With Pretreated Locally Advanced or Metastatic Her2-negative Breast Cancer
NCT01891227 ·Status: COMPLETED ·Phase: PHASE2
-
Intravenous RPR109881 in Male or Female Patients With Advanced Breast Cancer Who no Longer Respond to Anthracycline, Taxane and Capecitabine Treatment
NCT00087958 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
NCT04683679 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Pembrolizumab and Cryoablation in People With Breast Cancer
NCT06246968 ·Status: RECRUITING ·Phase: PHASE1
-
Safety Study in Subjects With Metastatic Breast Cancer Who Progressed After Taxanes Treatment.
NCT01050322 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer
NCT05190770 ·Status: COMPLETED ·Phase: PHASE2
-
All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer：a Multi-center, Multi-cohort Phase II Trial
NCT06636981 ·Status: RECRUITING ·Phase: PHASE2
-
Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer
NCT05288777 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
STereotactic Body Radiotherapy (SBRT) for Oligoprogressive Breast Cancer
NCT06489821 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Breast Cancer Trial of RPR109881 Versus Capecitabine in Male or Female Patients With Advanced Breast Cancer
NCT00081796 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer
NCT04690855 ·Status: TERMINATED ·Phase: PHASE2
-
Capecitabine and Radiotherapy in the Adjuvant Treatment of Resistant Breast Cancer
NCT03958721 ·Status: COMPLETED ·Phase: PHASE1
-
Standard Chemotherapy Compared With High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer
NCT00002755 ·Status: COMPLETED ·Phase: PHASE3
-
Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO
NCT05033756 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Lapatinib and Radiation Therapy in Treating Patients With Locally Recurrent or Chemotherapy-Refractory Locally Advanced or Metastatic Breast Cancer
NCT00379509 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC
NCT05103917 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer
NCT00829166 ·Status: COMPLETED ·Phase: PHASE3
-
Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer
NCT00320385 ·Status: COMPLETED ·Phase: PHASE3
-
Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)
NCT05128734 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Metastases-directed Radiotherapy in Addition to Standard Systemic Therapy in Patients With Oligometastatic Breast Cancer
NCT04495309 ·Status: COMPLETED ·Phase: NA
-
Stereotactic Ablative Body Radiotherapy (SABR) With Maintenance of Systemic Therapy Versus Physicians' Choice of Systemic Therapy for Oligoprogressive ER-positive, Her-2 Negative Breast Cancer II
NCT06882499 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700 ·Status: RECRUITING ·Phase: PHASE3
-
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
NCT01964924 ·Status: COMPLETED ·Phase: PHASE2